Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion Active Biotech, 23 May 2014 Accessed on 26 May 2014 from http://www.activebiotech.com/press-releases-1?pressurl=http://cws.huginonline.com/A/1002/PR/201405/1788087.xml. CommentRecommendBookmarkWatch